Alto Neuroscience (ANRO) EBIT (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of EBIT data on file, last reported at -$27.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 73.12% year-over-year to -$27.1 million; the trailing twelve-month figure through Mar 2026 stood at -$77.8 million (down 11.34% YoY), and the FY2025 full-year result was -$66.4 million, up 3.27% from the prior year.
• EBIT eased to -$27.1 million in Q1 2026, from -$17.1 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$7.2 million in Q1 2023 to a low of -$27.1 million in Q1 2026.
• A 4-year average of -$15.4 million and a median of -$15.7 million in 2025 frame the typical range for EBIT.
• Across the five-year window, EBIT tumbled 101.0% in 2024 and gained 20.84% in 2025, its largest moves.
• Tracing ANRO's EBIT over 4 years: stood at -$11.8 million in 2023, then tumbled by 44.47% to -$17.0 million in 2024, then slipped by 0.34% to -$17.1 million in 2025, then tumbled by 59.12% to -$27.1 million in 2026.
• Business Quant data shows ANRO's EBIT at -$27.1 million in Q1 2026, -$17.1 million in Q4 2025, and -$15.0 million in Q3 2025.